- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Ferrania reorganizes, attracts capital
European PACS and digital x-ray developer Ferrania Imaging Technologies is restructuring its European operations. Adrian Stevens will lead the European Life Imaging sales and marketing teams in Europe with direct responsibility for the European region,
European PACS and digital x-ray developer Ferrania Imaging Technologies is restructuring its European operations. Adrian Stevens will lead the European Life Imaging sales and marketing teams in Europe with direct responsibility for the European region, including Italy, Germany, U.K., Ireland, Scandinavia, Benelux, Switzerland, Austria, France, and Iberia. He will retain his responsibilities as managing director for Ferrania U.K. Ian Wilson will assume responsibility for the Life Imaging business, taking the position of business manager of the division for the U.K. and Nordic region.
ADT Partners, an international investment group, has agreed to acquire a significant stake in Ferrania. Permira Funds, formally called Schroder Ventures, will continue to hold a majority position.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
